Meta AnalysisID 3925
肾炎康复片联合氯沙坦钾治疗慢性肾小球肾炎的有效性与安全性的Meta分析
CRD42022345149
To systematically review the efficacy and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of Chronic glomerulonephritis.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3925
- Evidence Id
- 12483
- Core Evidence Id
- 12483
- Source Meta Analysis Id
- 3884
- Herb2 Meta Analysis Id
- HBMA003884
- Crd Id
- CRD42022345149
- Title
- Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of Chronic glomerulonephritis
- Review Question
- To systematically review the efficacy and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of Chronic glomerulonephritis.
- Study Type Included
- RCT
- Condition Being Studied
- The main indicators include effective rate，Secondary indicators mainly include serum creatinine (Scr ), Blood urea nitrogen (BUN), 24-hour urinary protein quantity, urine NAG enzyme and LKN-1.
- Participant
- Inclusion criteria: Study type: All prospective randomized controlled trials were included.Patients: All patients meet the criteria for diagnosis for chronic nephritis set by the World Health Organization (WHO). Intervention measurements: The control group was treated with SYKF tablets or losartan potassium tablet (50mg, Po, qd) alone and the experimental group was treated with SYKF tablets and losartan potassium tablet. Outcome indicators: 1. The main indicators include effective rate. Efficacy criteria are as follows: Significantly effective: clinical signs and symptoms are significantly alleviated, 24 h urine protein quantitative decrease >40% or urine protein decrease 2 +, urine sediment count red blood cell decrease> 40% or urine red blood cell decrease 2 +. Effective: clinical signs and symptoms are relieved, 24 hours urine protein quantitative decrease ≤ 40% or urine protein decrease 1 +. Invalid: clinical signs, symptoms, and related indicators are aggravated or not alleviated. Total effective rate = Significantly effective rate + effective rate. 2. Secondary indicators mainly include serum creatinine (Scr ), Blood urea nitrogen (BUN), 24-hour urinary protein quantity, urine NAG enzyme and LKN-1. Exclusion criteria: 1: Reviews, animal experiments, case reports and expert experience reports; 2: Repeated publications; 3: Researches where full-text data cannot be extracted for statistical analysis.
- Animal
- Human Disease Modelled
- Intervention
- Intervention measurements: the experimental group was treated with SYKF tablets and losartan potassium tablet.
- Comparator Control
- The control group was treated with SYKF tablets or losartan potassium tablet (50mg, Po, qd) alone
- Main Outcome
- The main indicators include effective rate，Secondary indicators mainly include serum creatinine (Scr ), Blood urea nitrogen (BUN), 24-hour urinary protein quantity, urine NAG enzyme and LKN-1.
- Outcome Measure
- Additional Outcome
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Antihypertensive Agents; Glomerulonephritis; Humans; Losartan; Tablets
- Contact
- Longxun Zhu [email protected]
- Organisational Affiliation
- Department of Pharmacy, Affiliated Hospital 2 of Nantong University
- Funding Source
- This work was supported by Nantong Health Commission Fund (No. QA2021007, QA2021006, QA2021014)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-07-08
- Registration Date
- 2022-07-18
- Anticipated Start Date
- 2021-08-01
- Anticipated Completion Date
- 2022-08-11
- Title Cn
- 肾炎康复片联合氯沙坦钾治疗慢性肾小球肾炎的有效性与安全性的Meta分析
- Title En
- Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of Chronic glomerulonephritis
- Bilingual Status
- complete